Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)

Program Status

Active, not recruiting

Phase

Phase 3

Prior Immunotherapy Allowed

No

CRC-directed Trial

Yes

Drugs

Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq

Tags

MSS/ MMRp

Comments

Phase III trial (STELLAR-003), only for MSS CRC patients.
Immunotherapy combination vs standard of care (SOC).
Immunotherapy arm: XL092 (tyrosine kinase inhibitor (TKI)) in combination with atezolizumab (anti PD-L1, checkpoint inhibitor, immunotherapy)
Standard of care arm: regorafenib (Stivarga)
Key inclusion criteria: no prior Stivarga, Lonsurf, or anti PD-L1/PD-1 immunotherapies.
Measurable disease.
Prior trials of the TKI XL092 (alone or in combinations) (STELLAR-001, STELLAR-002) show that is active and safe. Prior trials of other TKI (cabozantinib) plus immunotherapies (COSMIC-021, CAMILLA) showed meaningful activity in mCRC.
See Helpful Links

Helpful Links

Location Location Status
United States
Exelixis Clinical Site #65
Jonesboro, Alabama 72401
Active, not recruiting
Exelixis Clinical Site #30
Phoenix, Arizona 85004
Active, not recruiting
Exelixis Clinical Site #70
Tucson, Arizona 85719
Active, not recruiting
Exelixis Clinical Site #9
Duarte, California 91010
Active, not recruiting
Exelixis Clinical Site #55
La Jolla, California 92037
Active, not recruiting
Exelixis Clinical Site #77
Los Angeles, California 90095
Active, not recruiting
Exelixis Clinical Site #105
Orange, California 92868
Active, not recruiting
Exelixis Clinical Site #80
Santa Monica, California 90404
Active, not recruiting
Exelixis Clinical Site #5
Santa Rosa, California 95403
Active, not recruiting
Exelixis Clinical Site #82
Sylmar, California 91342
Active, not recruiting
Exelixis Clinical Site #58
Torrance, California 90505
Active, not recruiting
Exelixis Clinical Site #81
Whittier, California 90602
Active, not recruiting
Exelixis Clinical Site #125
New Haven, Connecticut 06510
Active, not recruiting
Exelixis Clinical Site #16
Miami Beach, Florida 33140
Active, not recruiting
Exelixis Clinical Site #60
Orlando, Florida 32804
Active, not recruiting
Exelixis Clinical Site #4
Marietta, Georgia 30060
Active, not recruiting
Exelixis Clinical Site #3
Joliet, Illinois 60435
Active, not recruiting
Exelixis Clinical Site #102
Indianapolis, Indiana 46250
Active, not recruiting
Exelixis Clinical Site #10
Westwood, Kansas 66205
Active, not recruiting
Exelixis Clinical Site #47
Lexington, Kentucky 40536
Active, not recruiting
Exelixis Clinical Site #7
New Orleans, Louisiana 70112
Active, not recruiting
Exelixis Clinical Site #22
Saint Louis, Missouri 63141
Active, not recruiting
Exelixis Clinical Site #8
Billings, Montana 59102
Active, not recruiting
Exelixis Clinical Site #1
Omaha, Nebraska 68130
Active, not recruiting
Exelixis Clinical Site #15
Albuquerque, New Mexico 87131
Active, not recruiting
Exelixis Clinical Site #17
Bronx, New York 10461
Active, not recruiting
Exelixis Clinical Site #11
New York, New York 10016
Active, not recruiting
Exelixis Clinical Site #59
New York, New York 10029
Active, not recruiting
Exelixis Clinical Site #74
Charlotte, North Carolina 28204
Active, not recruiting
Exelixis Clinical Site #6
Cincinnati, Ohio 45219
Active, not recruiting
Exelixis Clinical Site #12
Oklahoma City, Oklahoma 73142
Active, not recruiting
Exelixis Clinical Site #75
Portland, Oregon 97210
Active, not recruiting
Exelixis Clinical Site #106
Philadelphia, Pennsylvania 19107
Active, not recruiting
Exelixis Clinical Site #18
Pittsburgh, Pennsylvania 15212
Active, not recruiting
Exelixis Clinical Site #103
Pittsburgh, Pennsylvania 15232
Active, not recruiting
Exelixis Clinical Site #24
Greenville, South Carolina 29607
Active, not recruiting
Exelixis Clinical Site #56
Chattanooga, Tennessee 37404
Active, not recruiting
Exelixis Clinical Site #76
Nashville, Tennessee 37203
Active, not recruiting
Exelixis Clinical Site #133
Nashville, Tennessee 37232
Active, not recruiting
Exelixis Clinical Site #450
Fairfax, Virginia 22031
Active, not recruiting
Exelixis Clinical Site #14
Roanoke, Virginia 24014
Active, not recruiting
Exelixis Clinical Site #13
Seattle, Washington 98101
Active, not recruiting
Exelixis Clinical Site #32
Seattle, Washington 98104
Active, not recruiting
Exelixis Clinical Site #89
Seattle, Washington 98109
Active, not recruiting
Exelixis Clinical Site #2
Spokane, Washington 99208
Active, not recruiting
Australia
Exelixis Clinical Site #83
Albury 2640
Active, not recruiting
Exelixis Clinical Site #53
Bankstown 2200
Active, not recruiting
Exelixis Clinical Site #117
Bedford Park 5042
Active, not recruiting
Exelixis Clinical Site #97
Heidelberg 3084
Active, not recruiting
Exelixis Clinical Site #19
Melbourne 3002
Active, not recruiting
Exelixis Clinical Site #23
Melbourne 3021
Active, not recruiting
Exelixis Clinical Site #27
Port Macquarie 2444
Active, not recruiting
Exelixis Clinical Site #64
Woodville South 5011
Active, not recruiting
Belgium
Exelixis Clinical Site #43
Antwerp 2300
Active, not recruiting
Exelixis Clinical Site #51
Brussels 1200
Active, not recruiting
Exelixis Clinical Site #35
Namur 5000
Active, not recruiting
France
Exelixis Clinical Site #52
Besançon 25030
Active, not recruiting
Exelixis Clinical Site #84
Dijon 21079
Active, not recruiting
Exelixis Clinical Site #88
Herbault 34298
Active, not recruiting
Exelixis Clinical Site #71
Lyon 69008
Active, not recruiting
Exelixis Clinical Site #87
Marseille 13385
Active, not recruiting
Exelixis Clinical Site #38
Paris 75020
Active, not recruiting
Exelixis Clinical Site #93
Suresnes 92150
Active, not recruiting
Germany
Exelixis Clinical Site #127
Hannover, Niedersach 30625
Active, not recruiting
Exelixis Clinical Site #109
Dresden 01307
Active, not recruiting
Exelixis Clinical Site #113
Frankfurt am Main 60488
Active, not recruiting
Exelixis Clinical Site #61
Hamburg 20249
Active, not recruiting
Exelixis Clinical Site #63
Hamburg 22763
Active, not recruiting
Exelixis Clinical Site #91
München 81737
Active, not recruiting
Hong Kong
Exelixis Clinical Site #25
Hong Kong
Active, not recruiting
Exelixis Clinical Site #33
Hong Kong
Active, not recruiting
Hungary
Exelixis Clinical Site #128
Nyíregyháza, Szabolcs-Szatmar-Bereg County 4400
Active, not recruiting
Exelixis Clinical Site #41
Budapest 1097
Active, not recruiting
Exelixis Clinical Site #129
Budapest 1122
Active, not recruiting
Exelixis Clinical Site #48
Debrecen 4302
Active, not recruiting
Exelixis Clinical Site #122
Győr 9024
Active, not recruiting
Korea, Republic of
Exelixis Clinical Site #36
Goyang-si 10408
Active, not recruiting
Exelixis Clinical Site #29
Gyeonggi-do 14068
Active, not recruiting
Exelixis Clinical Site #28
Hwasun 58128
Active, not recruiting
Exelixis Clinical Site #37
Seongnam-si 13620
Active, not recruiting
Exelixis Clinical Site #34
Seoul 03080
Active, not recruiting
Exelixis Clinical Site #45
Seoul 03722
Active, not recruiting
Exelixis Clinical Site #66
Seoul 05505
Active, not recruiting
Exelixis Clinical Site #46
Seoul 06351
Active, not recruiting
Exelixis Clinical Site #54
Seoul 06591
Active, not recruiting
Exelixis Clinical Site #44
Seoul 08308
Active, not recruiting
Exelixis Clinical Site #40
Seoul
Active, not recruiting
New Zealand
Exelixis Clinical Site #57
Auckland 1023
Active, not recruiting
Exelixis Clinical Site #49
Dunedin 9016
Active, not recruiting
Exelixis Clinical Site #69
Hamilton 3204
Active, not recruiting
Exelixis Clinical Site #104
Wellington 6021
Active, not recruiting
Poland
Exelixis Clinical Site #20
Bydgoszcz 85-796
Active, not recruiting
Exelixis Clinical Site #68
Opole 45-061
Active, not recruiting
Exelixis Clinical Site #26
Siedlce 08-110
Active, not recruiting
Exelixis Clinical Site #42
Tomaszów Mazowiecki 97-200
Active, not recruiting
Exelixis Clinical Site #31
Warszawa 02-507
Active, not recruiting
Portugal
Exelixis Clinical Site #108
Almada 2805-267
Active, not recruiting
Exelixis Clinical Site #120
Coimbra 3000-075
Active, not recruiting
Exelixis Clinical Site #99
Guimarães 4835-044
Active, not recruiting
Exelixis Clinical Site #131
Lisboa 1500-650
Active, not recruiting
Exelixis Clinical Site #124
Lisboa 1649-035
Active, not recruiting
Exelixis Clinical Site #96
Lisboa 400-038
Active, not recruiting
Singapore
Exelixis Clinical Site #132
Singapore 119228
Active, not recruiting
Exelixis Clinical Site #100
Singapore 168583
Active, not recruiting
Exelixis Clinical Site #39
Singapore 217562
Active, not recruiting
Exelixis Clinical Site #98
Singapore 258499
Active, not recruiting
Exelixis Clinical Site #94
Singapore 329563
Active, not recruiting
Spain
Exelixis Clinical Site #78
Barcelona 08023
Active, not recruiting
Exelixis Clinical Site #21
Barcelona 08025
Active, not recruiting
Exelixis Clinical Site #86
Barcelona 08035
Active, not recruiting
Exelixis Clinical Site #112
Barcelona 08908
Active, not recruiting
Exelixis Clinical Site #95
Lleida 25198
Active, not recruiting
Exelixis Clinical Site #116
Madrid 28007
Active, not recruiting
Exelixis Clinical Site #72
Madrid 28034
Active, not recruiting
Exelixis Clinical Site #67
Madrid 28041
Active, not recruiting
Exelixis Clinical Site #79
Madrid 28050
Active, not recruiting
Exelixis Clinical Site #90
Valencia 46014
Active, not recruiting
Exelixis Clinical Site #121
Zaragoza 50009
Active, not recruiting
Taiwan
Exelixis Clinical Site #119
Guishan 333
Active, not recruiting
Exelixis Clinical Site #85
Kaohsiung 807
Active, not recruiting
Exelixis Clinical Site #107
Kaohsiung 833
Active, not recruiting
Exelixis Clinical Site #118
Liuying 73657
Active, not recruiting
Exelixis Clinical Site #73
Taichung 40447
Active, not recruiting
Exelixis Clinical Site #101
Tainan 704
Active, not recruiting
Thailand
Exelixis Clinical Site #62
Chiang Mai 50200
Active, not recruiting
Exelixis Clinical Site #92
Hat Yai 90110
Active, not recruiting
United Kingdom
Exelixis Clinical Site #130
Bristol, England BS2 8ED
Active, not recruiting
Exelixis Clinical Site #110
Birmingham B95SS
Active, not recruiting
Exelixis Clinical Site #111
Edinburgh EH42XU
Active, not recruiting
Exelixis Clinical Site #123
London EC1A 7BE
Active, not recruiting
Exelixis Clinical Site #114
London W1G 6AD
Active, not recruiting
Exelixis Clinical Site #115
Romford RM70AG
Active, not recruiting
Exelixis Clinical Site #126
Sutton SM2 5PT
Active, not recruiting

Inclusion Criteria

Inclusion Criteria:

* Subjects with histologically or cytologically confirmed adenocarcinoma of the colon or rectum.

* Documented RAS status (mutant or wild-type [WT]), by tissue-based analysis.
* Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis.
* Has received standard-of-care (SOC) anticancer therapies as prior therapy for metastatic CRC and has radiographically progressed, is refractory or intolerant to these therapies.

* Systemic SOC anticancer therapy if approved and available in the country where the subject is randomized.
* Radiographic progression during treatment with or within 4 months following the last dose of the most recent approved SOC chemotherapy regimen.
* Measurable disease according to RECIST v1.1 as determined by the Investigator.
* Available archival tumor biopsy material. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization.
* Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs) related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
* Age 18 years or older on the day of consent.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Adequate organ and marrow function.
* Fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and after the last dose of treatment.
* Female subjects of childbearing potential must not be pregnant at screening.

Exclusion Criteria

Exclusion Criteria:

* Prior treatment with XL092, regorafenib, trifluridine/tipiracil, or PD-L1/PD-1 targeting immune checkpoint inhibitors (ICIs).
* Receipt of a small molecule kinase inhibitor (including investigational agents) within 2 weeks before randomization.
* Receipt of any type of anticancer antibody therapy, systemic chemotherapy, or hormonal anti-cancer therapy within 3 weeks (or bevacizumab within 4 weeks) before randomization.
* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before randomization.
* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before randomization.
* Subject has uncontrolled, significant intercurrent or recent illness.
* Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 4 weeks prior to randomization.
* Systemic treatment with, or any condition requiring, either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to randomization.
* Corrected QT interval calculated by the Fridericia formula (QTcF) > 460 ms within 10 days before randomization.
* History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent.
* Pregnant or lactating females.
* Inability to swallow study treatment formulation, inability to receive IV administration, or presence of GI condition that might affect the absorption of study drug.
* Previously identified allergy or hypersensitivity to components of the study treatment formulations.
* Any other active malignancy or diagnosis of another malignancy within 2 years before randomization. Exceptions are noted in the protocol.
* Administration of a live, attenuated vaccine within 30 days before randomization.

NCT ID

NCT05425940

Date Trial Added

2022-06-21

Updated Date

2024-07-05